^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    obrixtamig (BI 764532)

    i
    Other names: BI 764532, OBT620, BI-764532, OBT-620, BI764532, OBT 620
    Company:
    Boehringer Ingelheim, Oxford BioTherapeutics
    Drug class:
    CD3 agonist, DLL3 inhibitor
    Related drugs:
    16d
    DAREONTM-9: DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy (clinicaltrials.gov)
    P1, N=90, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting | Trial completion date: Apr 2027 --> Jul 2027
    Enrollment closed • Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    topotecan • obrixtamig (BI 764532)
    28d
    Structural and functional insights into CD3 bispecific antibodies targeting DLL3 in cancer immunotherapy. (PubMed, Med Oncol)
    This study systematically characterized three clinical-stage CD3×DLL3 BsAbs, Tarlatamab (AMG757), BI764532 and HPN328, via structural modeling, T-cell activation assays, cytokine profiling, and tumor cytotoxicity tests. BI764532 demonstrated a balanceed efficacy (ORR 18% in SCLC), while Tarlatamab achieved an ORR range of 13-40% across clinical trials. IS distance and epitope binding are strongly correlated with efficacy and safety of DLL3-targeted BsAbs, providing a critical framework for optimizing T-cell engager design in cancer immunotherapy.
    Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    obrixtamig (BI 764532) • Imdelltra (tarlatamab-dlle) • gocatamig (MK-6070)
    28d
    DAREON-5: DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers (clinicaltrials.gov)
    P2, N=174, Recruiting, Boehringer Ingelheim | Trial completion date: Jul 2027 --> Feb 2028 | Trial primary completion date: Jan 2027 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    obrixtamig (BI 764532)
    3ms
    DAREON-8: DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=46, Active, not recruiting, Boehringer Ingelheim | Trial primary completion date: Dec 2025 --> Sep 2026
    Trial primary completion date
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • etoposide IV • obrixtamig (BI 764532)
    3ms
    DareonTM: DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers (clinicaltrials.gov)
    P2, N=174, Recruiting, Boehringer Ingelheim | Trial primary completion date: Oct 2026 --> Jan 2027
    Trial primary completion date
    |
    obrixtamig (BI 764532)
    4ms
    DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers (clinicaltrials.gov)
    P1, N=55, Recruiting, Boehringer Ingelheim | Trial completion date: Aug 2026 --> Apr 2027 | Trial primary completion date: Jul 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • etoposide IV • obrixtamig (BI 764532)
    4ms
    A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3 (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    obrixtamig (BI 764532)
    4ms
    A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer (clinicaltrials.gov)
    P1, N=12, Recruiting, Boehringer Ingelheim | Trial completion date: Jul 2026 --> Nov 2026 | Trial primary completion date: Jan 2026 --> May 2026
    Trial completion date • Trial primary completion date
    |
    obrixtamig (BI 764532)
    4ms
    A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 (clinicaltrials.gov)
    P1, N=45, Active, not recruiting, Boehringer Ingelheim | Phase classification: P1/2 --> P1 | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2025
    Phase classification • Trial completion date • Trial primary completion date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    obrixtamig (BI 764532) • ezabenlimab (BI 754091)
    5ms
    A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 (clinicaltrials.gov)
    P1, N=300, Recruiting, Boehringer Ingelheim | Trial completion date: Dec 2025 --> Feb 2027 | Trial primary completion date: Sep 2025 --> Aug 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    obrixtamig (BI 764532)
    5ms
    DAREON-8: DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=46, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • etoposide IV • obrixtamig (BI 764532)
    6ms
    A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 (clinicaltrials.gov)
    P1/2, N=45, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    obrixtamig (BI 764532) • ezabenlimab (BI 754091)